Status:
UNKNOWN
Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Drug Drug Interaction
Eligibility:
All Genders
19-45 years
Phase:
PHASE1
Brief Summary
This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers...
Eligibility Criteria
Inclusion
- over 19 year old
Exclusion
- Galactose intolerance
- Lapp lactase deficiency
Key Trial Info
Start Date :
October 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06119958
Start Date
October 27 2023
End Date
December 1 2023
Last Update
November 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
H Plus YANGJI Hospital
Seoul, South Korea